461 related articles for article (PubMed ID: 29475164)
1. Thiazolidinediones as antidiabetic agents: A critical review.
Nanjan MJ; Mohammed M; Prashantha Kumar BR; Chandrasekar MJN
Bioorg Chem; 2018 Apr; 77():548-567. PubMed ID: 29475164
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
[TBL] [Abstract][Full Text] [Related]
3. Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present.
Yasmin S; Jayaprakash V
Eur J Med Chem; 2017 Jan; 126():879-893. PubMed ID: 27988463
[TBL] [Abstract][Full Text] [Related]
4. The Journey of Thiazolidinediones as Modulators of PPARs for the Management of Diabetes: A Current Perspective.
Ahsan W
Curr Pharm Des; 2019; 25(23):2540-2554. PubMed ID: 31333088
[TBL] [Abstract][Full Text] [Related]
5. Experimental approaches to study PPAR gamma agonists as antidiabetic drugs.
Vázquez M; Silvestre JS; Prous JR
Methods Find Exp Clin Pharmacol; 2002 Oct; 24(8):515-23. PubMed ID: 12500431
[TBL] [Abstract][Full Text] [Related]
6. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
Mansour M
Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
[TBL] [Abstract][Full Text] [Related]
7. Insulin resistance and PPAR insulin sensitizers.
Bhatia V; Viswanathan P
Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
[TBL] [Abstract][Full Text] [Related]
8. Identification of plant extracts with potential antidiabetic properties: effect on human peroxisome proliferator-activated receptor (PPAR), adipocyte differentiation and insulin-stimulated glucose uptake.
Christensen KB; Minet A; Svenstrup H; Grevsen K; Zhang H; Schrader E; Rimbach G; Wein S; Wolffram S; Kristiansen K; Christensen LP
Phytother Res; 2009 Sep; 23(9):1316-25. PubMed ID: 19172665
[TBL] [Abstract][Full Text] [Related]
9. Rational drug design and PPAR agonists.
Perfetti R; D'Amico E
Curr Diab Rep; 2005 Oct; 5(5):340-5. PubMed ID: 16188168
[TBL] [Abstract][Full Text] [Related]
10. PPAR Agonists and Metabolic Syndrome: An Established Role?
Botta M; Audano M; Sahebkar A; Sirtori CR; Mitro N; Ruscica M
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29662003
[TBL] [Abstract][Full Text] [Related]
11. [Nuclear receptors PPAR as a drug target in metabolic disorders].
Stolarczyk M; Gutman W; Derlacz RA
Postepy Biochem; 2011; 57(2):207-14. PubMed ID: 21913422
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotective effects of thiazolidinediones, peroxisome proliferator-activated receptor-gamma agonists.
Yue TL
Drugs Today (Barc); 2003 Dec; 39(12):949-60. PubMed ID: 14747840
[TBL] [Abstract][Full Text] [Related]
13. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
Huang TH; Roufogalis BD
Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
[TBL] [Abstract][Full Text] [Related]
14. MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema.
Gregoire FM; Zhang F; Clarke HJ; Gustafson TA; Sears DD; Favelyukis S; Lenhard J; Rentzeperis D; Clemens LE; Mu Y; Lavan BE
Mol Endocrinol; 2009 Jul; 23(7):975-88. PubMed ID: 19389808
[TBL] [Abstract][Full Text] [Related]
15. [Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
Sugiyama Y; Murase K; Ikeda H
Nihon Rinsho; 2000 Feb; 58(2):370-5. PubMed ID: 10707560
[TBL] [Abstract][Full Text] [Related]
16. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
Lecka-Czernik B
Curr Osteoporos Rep; 2010 Dec; 8(4):178-84. PubMed ID: 20809203
[TBL] [Abstract][Full Text] [Related]
17. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
Tenenbaum A; Motro M; Fisman EZ
Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
[TBL] [Abstract][Full Text] [Related]
18. Thiazolidinedione safety.
Kung J; Henry RR
Expert Opin Drug Saf; 2012 Jul; 11(4):565-79. PubMed ID: 22616948
[TBL] [Abstract][Full Text] [Related]
19. Evolution of peroxisome proliferator-activated receptor agonists.
Chang F; Jaber LA; Berlie HD; O'Connell MB
Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
[TBL] [Abstract][Full Text] [Related]
20. Three-dimensional quantitative structure-activity relationships (3D-QSAR) of antidiabetic thiazolidinediones.
Kurogi Y
Drug Des Discov; 1999 Aug; 16(2):109-18. PubMed ID: 10533807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
